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INTRODUCTION
Granulomatous dermatitis (GD) describes disor-
ders in which mixed inflammatory infiltrates
composed primarily of histiocytes invade the skin.
The pathogenesis of GD is unknown; however, GD
has been noted to occur in areas previously affected
by trauma, sun damage, or infection.1 When GD
presents at the same site of a healed, unrelated skin
disease, it falls within the category of aWolf’s isotopic
response.2 The regional restriction of a Wolf’s iso-
topic response is proposed to occur due to an area of
localized immunocompromise known as an immu-
nocompromised district.3 This immunocompromised
district is believed to result from various types of
cutaneous damage that hinder lymph circulation, like
chronic regional lymphedema or prior herpes virus
infection (eg, varicella zoster virus [VZV] and herpes
simplex virus [HSV]).3 Postherpetic isotopic response
(PHIR) is the most commonly reported isotopic
response, and more cases of PHIR-GD have been
reported than any other type of isotopic response.3 It
can occur within the same dermatomal distribution
either immediately after primary lesion resolution
(VZV[HSV) or many years later.3 Persistent VZV
DNA has been detected in PHIR lesions within
4 weeks after an acute episode4,5 but not after 7
weeks.6,7 The presence of viral DNA in some lesions
has led to the proposal that VZV glycoproteins (gpI/
II)may still be expressed at a sufficient level to initiate
granuloma formation.8
Since the first report of granuloma annulare (GA)
as an isotopic response,9 38% of the 32 cases have
been reported in the setting of immunocompro-
mise.10 We now add 5 unreported cases and 16
literature cases (not reviewed in prior meta-analyses)
of immunocompromised PHIR-GD. Our review of
the literature has also added 23 cases of
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nonimmunocompromised PHIR-GD. Our analysis of
33 immunocompromised and 43 immunocompetent
cases highlights PHIR-GD associations with immu-
nocompromise, chronic lymphocytic leukemia
(CLL), and male sex.
METHODS
We conducted a retrospective study of 5 immu-
nocompromised PHIR-GD patients at Barnes Jewish
Hospital in St Louis, Missouri between 2008 and
2015. Through a literature search of PubMed, we
reviewed all previous cases of PHIR-GD. Search
terms included Wolf’s isotopic response, postherpetic
isotopic response, granulomatous dermatitis, granu-
loma annulare, and perturbations of these terms.




A 53-year-old white woman with systemic lupus
erythematosus (SLE), Sj€ogren syndrome (SS), and
IgM deficiency on methotrexate, Plaquenil, predni-
sone, and sulfasalazine presented with right V1
dermatome VZV reactivation. Treatment included
valacyclovir, tobramycin ophthalmic ointment, and
gabapentin. Less than a month after the lesions
resolved, an erythematous, alopecic plaque
appeared in the same dermatome (Fig 1; SLE1SS)
complicated by severe postherpetic neuralgia (PHN)
and trigeminal trophic syndromewith ulceration and
superinfection (methicillin-resistant Staphylococcus
aureus, Candida keratitis). Biopsy found no viral
cytopathic changes (Fig 1; SLE1SS). HSV/VZVassays
were negative. She received valacyclovir, corticoste-
roids (topical, intralesional, oral), and calcineurin
inhibitors (tacrolimus, pimecrolimus) for her PHIR-
GD. Her PHN required oral gabapentin, pregabalin,
duloxetine, hydroxyzine, and topical lidocaine.
Autoimmune treatments were replaced with abata-
cept 6 months after PHIR-GD onset. Over 19.5
months, her cutaneous disease and PHN significantly
improved, but her PHN never resolved completely.
Case 2
A 56-year-old white man with a history of acute
myelogenous leukemia (AML) treated with chemo-
therapy and unrelated donor stem cell transplant
(SCT) later complicated by chronic graft-versus-host
disease presented for suture removal after Mohs
micrographic surgery for squamous cell carcinoma
of the left side of the forehead. He was found to have
VZV reactivation of the left V1 dermatome. He
received intravenous acyclovir, oral valacyclovir,
and gabapentin for PHN. Less than a month later,
an erythematous, sclerotic plaque developed in the
Fig 1. Clinical and histologic images. Four of the immunocompromised patients with
granulomatous PHIR from this case series are shown with their clinical photographs above
and the corresponding H&E pathology immediately below. Inset images show magnified areas
of rash/histology. Immunocompromise etiology and microscopic magnifications are listed. No
clinical/histologic images were available for the heart transplant subject in our case series.
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same dermatome consistent with GD on biopsy (Fig
1; AML1SCT). He was treated topically (desonide,
pimecrolimus) and orally (valacyclovir, prednisone,
minocycline, dicloxacillin). PHIR-GD skin lesions
and PHN persisted despite treatment at 1-year
follow-up.
Case 3
A 57-year-old African-American woman with a
history of multiple myeloma (MM) treated with
chemotherapy followed by autologous SCT pre-
sented with right upper extremity (dermatomes C5-
C6) VZVreactivation. She was treated with high-dose
acyclovir. Two weeks later, flat-topped, violaceous,
polygonal papules appeared among resolving VZV
lesions (Fig 1; MM1SCT). Biopsy found poorly
formed epithelioid granulomas in the superficial
dermis with extension to the dermoepidermal junc-
tion and no lichenoid infiltrate or viral cytopathic
change (Fig 1; MM1SCT). Grocott methenamine
silver stain, and acid-fast bacilli stains were negative.
PHIR-GD treatment (hydroxyzine, high potency
topical steroids, intralesional Kenalog) resulted in
significant improvement by 5 months. Complete
resolution of cutaneous findings was noted at 2-
year follow-up, although PHN persisted requiring
gabapentin, topical lidocaine, and epidural steroid
injections.
Case 4
A 73-year-old white man with a history of heart
transplant in 1985 presented with disseminated VZV
reactivation (right V3 and C5 dermatomes). At pre-
sentation, his immunosuppressive regimen included
cyclosporine, azathioprine, and prednisone. VZV
treatment included valacyclovir and gabapentin for
PHN. Within 3 weeks, erythematous papules devel-
oped interspersed within his healing VZV lesions
(right C5 dermatome) with significant PHN. VZV
polymerase chain reaction was negative for both
lesions. Biopsy found a prominent interstitial gran-
ulomatous process with necrobiosis and no viral
cytopathic changes. Gram and Fite stains were
negative. PHIR-GD was treated with clobetasol.
Case 5
A 71-year-old African-American woman with
CLL complicated by immune thrombocytopenic
purpura presented with VZV reactivation (left C5-
T1 dermatomes) and significant PHN 1 month after
rituximab treatment and ibrutinib initiation. She
initially received valacyclovir, gabapentin, and
acetaminophen-hydrocodone. Once the lesions
resolved, she was treated with acyclovir prophylaxis.
Eight months later, firm, erythematous papules in an
annular pattern developed in a left-sided C5-8 dis-
tribution consistent with PHIR-GD (Fig 1; CLL).
Biopsy found superficial and deep perivascular
loose granulomas and lymphocytes (Fig 1; CLL).
Gram, Grocott methenamine silver stain, and Fite
stains were negative. Clobetasol cream improved her
PHIR-GD by her follow-up at 4 months.
Summary of reported cases
These 5 cases were integrated into a review of all
published immunocompromised PHIR-GD clinical
and histologic data (Supplemental Figs 1 and 2). For
comparison, PHIR granulomatous vasculitis and
folliculitis cases were summarized separately
(Supplemental Figs 3 and 4). The average age of
PHIR-GD presentation was similar in immunocom-
promised patients (656 11 years) and immunocom-
petent patients (59 6 18 years). Although most
PHIR-GD cases were initiated by VZV ([96%), HSV
was identified in 9% of immunocompromised PHIR-
GD cases. Similar to prior literature, herpes virus
infection occurred on average 4.2 months before
PHIR (range, 0.1 to 36), and most cases resolved
within 1 to 2 years with conservative GD manage-
ment, although our 5 new cases all were complicated
by severe PHN.
Immunocompromise analysis
Immunocompromise in PHIR-GD appears more
commonly (43%) than previously reported (38%)
(Fig 2, A). We have expanded the previously
identified immunocompromised context for PHIR-
GD (chemotherapy or hematopoietic malignancy) to
include HIV, myelodysplastic syndrome, solid organ
transplant, and connective tissue disease (Fig 2, B).
CLL remained the most common cause of immuno-
compromise in granulomatous PHIR patients (44%
all cases/48% GD). Interestingly, our work suggests
that sex may play a role in PHIR-GD, as immuno-
compromised men appeared particularly susceptible
to granulomatous PHIR independent of their higher
incidence of CLL (Fig 2, C ). Conversely, granuloma-
tous PHIR in immunocompetent patients is far more
frequent in women (Fig 2, C ) paralleling the
increased occurrence of GA in women.1
DISCUSSION
Nearly half of PHIR-GD cases (33 of 76; 43%) have
been reported in immunocompromised patients.
Immunocompromise likely worsens the regional
neuroimmune axis imbalance caused by herpetic
nerve injury and thereby increases the likelihood of
PHIR-GD.11 This hypothesis is supported by recent
PHIR-GD work demonstrating perineurovascular
lymphohistiocytic infiltrates.12 Further, the severe
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PHN of patients both in our study and prior
publications may reflect this proposed neuroim-
mune imbalance. We recommend that practitioners
aggressively manage these symptoms particularly in
immunocompromised PHIR-GD patients. Beyond
local neuroimmune effects, the overrepresentation
of CLL in our PHIR-GD patients (16 of 33; 48%)
compared with baseline CLL incidence (0.5%) may
help illuminate what humoral and cell-mediated
impairments led to granulomatous PHIR. The
upregulation of specific cell surface proteins on
adaptive immune cells (Fig 2, D),13 immune cell-
mediated hampered lymph drainage,13 and
increased tumor necrosis factor-a in CLL may help
drive granuloma formation (Fig 2, D). Future studies
of this phenomenon are needed to determine which
facet(s) of CLL immunocompromise favors PHIR-
GD, and we believe these studies will shed light on
both PHIR (GD and other responses) and CLL.
Although CLL association with PHIR-GD had been
Fig 2. Immunocompromise and granulomatous PHIR. A, The presence or absence of
immunocompromise in all published cases of granulomatous PHIR are summarized and
separated by type of inflammation. PHIR-GD granulomatous dermatitis encompasses sarcoidal
and nonsarcoidal (ie, GA and GA variants). B, Cases of PHIR-GD from the most recent meta-
analysis before this publication are compared with the cases added by this work. The types of
immunocompromise are listed and highlight the predominance of CLL in both studies. C, The
male/female ratio for each type of granulomatous PHIR was calculated as a function of
immunocompromise. Granulomatous PHIR folliculitis is not included, as there were too few
cases to include in this analysis. D, Model of how CLL immunocompromise could lead to
increased granulomatous response through both the T- and B-cell axes is shown. The
upregulated CLL B-cell factors impair immunologic synapse formation, promote Treg
expansion, and impair T cell activation/proliferation. Upregulated CLL T-cell CD30 impairs
B-cell isotype switching, increases B-cell sensitivity to FasL-mediated apoptosis, and increases
tumor necrosis factor-a production.
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previously noted, male predominance in immuno-
compromised PHIR-GD has not been previously
identified. It is particularly striking because of the
reported approximately 33% increased incidence of
VZV in women over men14 and the increased
incidence of granuloma annulare in women over
men (2.5:1),1 which we also observed in our review
of immunocompetent patients with PHIR-GD (2.9:1
overall, 2.6:1 for PHIR-GD). Although the male/
female ratio in CLL (1.5:1) may account for part of
themale predominance in PHIR-GD (2.8:1), it cannot
account entirely for this observation. Although we
do not yet understand the role of sex in PHIR-GD, we
recommend screening men with PHIR-GD for im-
munocompromise (particularly CLL) and aggres-
sively treating PHN in these patients to improve
clinical outcomes. We hope that these cases and our
literature review will spark future investigations to
improve our understanding of PHIR, granulomatous
reactions, and CLL.
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Supplemental Fig 1. Clinical summary of immunosuppressed PHIR-GD cases. Clinical data
including patient characteristics, immunosuppression, virus, and treatment for all reported
cases of PHIR-GD and the 5 cases reported in this manuscript are summarized.
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Supplemental Fig 2. Histologic summary of immunosuppressed PHIR-GD cases. Patient
characteristics (age, sex, immunosuppression) are listed next to available histologic data for all
reported cases of PHIR-GD and the 5 cases reported in this manuscript.
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Supplemental Fig 3. Clinical summary of immunosuppressed PHIR-GV/GF cases. Clinical
data including patient characteristics, immunosuppression, virus, and treatment for all reported
cases of PHIR-GV/GF (granulomatous vasculitis/folliculitis) are summarized.
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Supplemental Fig 4. Histologic summary of immunosuppressed PHIR-GF/GV cases. Patient
characteristics (age, sex, immunosuppression) are listed next to available histologic data for all
reported cases of PHIR-GF/GV.
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